Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CETP | P11597 | 4/20 | 0.97 |
| ▸ | THRB | P10828 | 1/20 | 0.97 |
| ▸ | MEN1 | O00255 | 1/20 | 0.97 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.97 |
| ▸ | ASAH1 | Q13510 | 2/20 | 0.76 |
| ▸ | TP53 | P04637 | 2/20 | 0.73 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.73 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.73 |
| ▸ | MAPT | P10636 | 1/20 | 0.73 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.73 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.73 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.73 |
| ▸ | DEGS1 | O15121 | 1/20 | 0.72 |
| ▸ | ASAH2 | Q9NR71 | 2/20 | 0.69 |
| ▸ | PLA2G4A | P47712 | 4/20 | 0.67 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.63 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.60 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30167971 | 1.00 | CETP (0.97) | CETPTHRBMEN1KMT2AASAH1 | |
| SCHEMBL20152381 | 1.00 | CETP (0.97) | CETPTHRBMEN1KMT2AASAH1 | |
| SCHEMBL31276708 | 1.00 | CETP (0.97) | CETPTHRBMEN1KMT2AASAH1 | |
| SCHEMBL30915241 | 1.00 | CETP (0.97) | CETPTHRBMEN1KMT2AASAH1 | |
| SCHEMBL2734386 | 1.00 | CETP (0.97) | CETPTHRBMEN1KMT2AASAH1 | |
| SCHEMBL31277312 | 1.00 | CETP (0.97) | CETPTHRBMEN1KMT2AASAH1 | |
| SCHEMBL31277666 | 1.00 | CETP (0.97) | CETPTHRBMEN1KMT2AASAH1 | |
| SCHEMBL20450780 | 1.00 | CETP (0.97) | CETPTHRBMEN1KMT2AASAH1 | |
| SCHEMBL22855979 | 1.00 | CETP (0.97) | CETPTHRBMEN1KMT2AASAH1 | |
| SCHEMBL30498995 | 1.00 | CETP (0.97) | CETPTHRBMEN1KMT2AASAH1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3229811-B1 | PREVENTION AND TREATMENT OF INFLAMMATORY CONDITIONS | GRI BIO INC (US) | 2021-02-24 | — | — | EP | disclosed |
| WO-2016094226-A1 | PREVENTION AND TREATMENT OF INFLAMMATORY CONDITIONS | GLYCOREGIMMUNE, INC. (US) | 2016-06-16 | — | — | WO | disclosed |
| US-20160158258-A1 | PREVENTION AND TREATMENT OF INFLAMMATORY CONDITIONS | ALTIUM GROWTH FUND, LP | 2016-06-09 | — | — | US | disclosed |
| US-7629385-B2 | Sphingolipid-derived pharmaceutical compositions | MAX-PLANCK-Gesellschaft zur Förderung der Wissenschaften e.V. (DE) | 2009-12-08 | — | — | US | disclosed |
| US-20080090913-A1 | Sphingolipid-Derived Phamaceutical Compositions | JADO TECHNOLOGIES GMBH (DE) | 2008-04-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080090913-A1 | Sphingolipid-Derived Phamaceutical Compositions | SGMS1, SGMS2, SMPD2 | CETP 32/4885THRB 3943/4885MEN1 3394/4885 |
| US-20160158258-A1 | PREVENTION AND TREATMENT OF INFLAMMATORY CONDITIONS | RXRA, RXRG, CX3CR1 | CETP 693/4885THRB 3055/4885MEN1 4785/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.